SOLVE FSHD Invests US $1 Million in miRecule
Posted on October 3rd, 202210/3/22
Filed under: FSHD Research
Our look is new. Our purpose is the same. Learn more about our brand evolution.
Our look is new. Our purpose is the same. Learn more about our brand evolution.
Trial has FDA approval. Start dates and locations have not yet been determined. Update as of 11/21/2024: AOC 1020 is now being referred to as Del-brax. San Diego-based Avidity Biosciences […]
AOC1020 will be the first RNA therapy to be tried in FSHD Avidity Biosciences announced today that it had received investigational new drug (IND) clearance from the U.S. Food and […]
Report from the FSHD Society’s 29th annual International Research Congress by Alexandra Belayew, PhD, Mons, Belgium This year’s congress (June 16-17) opened with a keynote presentation by Lexi Pappas, who […]
Part of our battle plan to ensure patients will have access to treatments by June Kinoshita, FSHD Society The FSHD Society is undertaking a major study of the full socioeconomic […]